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Hypoxic ischaemic insults during labour remain an important 
cause of brain injury in term and near-term infants.1 Brain 
injury that occurs in this way is an evolving process and the 
clinical manifestation of this injury is termed hypoxic ischaemic 
encephalopathy (HIE).2
Several animal studies have shown that the evolving brain 
injury in newborn animals following a hypoxic ischaemic insult 
is potentially amenable to neuroprotective rescue therapy in 
the form of cerebral hypothermia.3-7 Focal cerebral cooling, with 
mild systemic cooling, achieves neuroprotection with fewer 
systemic complications than deep whole-body cooling.8, 9
In 1998, Gunn et al.10 published a safety study using a cooling 
coil that circulated water at 10°C around the head. The scalp 
temperature of the cooled infants fell to 28°C and the rectal 
temperature was 35.7 ± 0.2°C. In this study, no significant 
adverse effects of cooling were detected if the core temperature 
was maintained above 34.2°C. Following the initial safety 
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Objective. The main objective of this study was to study the 
safety and efficacy of a simple, cost-effective method of 
selective head cooling with mild systemic hypothermia in 
newborn infants with hypoxic ischaemic encephalopathy. 
Design. Ethical approval was obtained for a randomised 
controlled study in which 20 asphyxiated neonates with 
clinical signs of hypoxic ischaemic encephalopathy would be 
randomised into cooled and non-cooled groups. However, after 
cooling the first 4 babies, it was clear that repeated revisions to 
the cooling technique had to be made which was inappropriate 
in the context of a randomised controlled trial. The study was 
therefore stopped and the data for the 4 cooled infants are 
presented here in the form of a technical report. Hypothermia 
was achieved by applying an insulated ice cap to the heads of 
the infants and replacing it at 2 - 3-hourly intervals, aiming to 
achieve a target rectal temperature of 35 - 35.5°C and a target 
scalp temperature of 10 - 28°C.
Setting. This study was carried out between July 2000 and 
September 2001 in the neonatal units of Groote Schuur Hospital 
and Mowbray Maternity Hospital, Cape Town.
Subjects. Term infants with signs of encephalopathy were 
recruited within the first 8 hours of life if they had required 
resuscitation at birth and had significant acidosis within the 
first hour of life.
Results. Target rectal temperature was achieved in all infants, 
but large variations in incubator and scalp temperatures 
occurred in 3 of the 4 infants. Reducing the target core 
temperature in a stepwise manner did not prevent excessive 
temperature variation and resulted in a longer time to 
reach target temperature. There was least variation in scalp 
temperature when the ice pack was covered in two layers 
of mutton cloth before application, but the resulting scalp 
temperatures were above the target temperature. The maximum 
scalp temperature variation was reduced from 22°C to 12°C 
using this method. Nasopharyngeal temperatures varied 
excessively within less than a minute, suggesting that air 
cooling via mouth breathing was occurring. The surface site 
that correlated best with deep rectal temperature was the back, 
with the infant supine. During cooling, the respiratory rate 
and heart rate dropped while the mean arterial blood pressure 
was elevated. There were no irreversible adverse events due 
to cooling, but infants did become agitated and exhibited 
shivering which required sedation and analgesia.
Conclusions. Nasopharyngeal temperature monitoring was 
not reliable as an acute clinical indicator of brain temperature 
in these spontaneously breathing infants, and the back 
temperature in supine infants correlated better with deep 
rectal temperature than did exposed skin temperature. This 
method of cooling achieved systemic cooling but there were 
large variations in regional temperatures in 3 of the 4 infants. 
The variations in temperature were probably due to the 
excessive cooling effect of the ice cap, coupled with the use 
of external heating to maintain systemic temperature at 35 - 
35.5°C. Variation in temperature was reduced when additional 
insulation was provided. However, the additional insulation 
resulted in the loss of the selective cerebral cooling effect. This 
cooling technique was therefore not an appropriate method of 
selective head cooling, but did successfully induce systemic 
hypothermia. This method of insulating an ice cap could 
therefore be used to induce whole-body cooling but the use of 
lower core temperatures of 33 - 34°C is recommended as this 
will probably result in fewer regional temperature fluctuations. 
Ideally a more uniform method of cooling should be used. 
S Afr Med J 2006; 96: 976-981.
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study by Gunn et al.,10 we sought to devise a simpler form of 
head cooling that could be used in developing countries. 
Ice packs have been applied to the heads of neonates during 
cardiopulmonary bypass surgery11 and cooling caps at -30°C, 
covered in cloth, were applied to piglets’ heads after cardiac 
arrest and resuscitation, with no local complications.12 We 
therefore designed this study to pilot a simple insulated ice 
pack, aiming for similar temperatures to those described by 
Gunn et al.10
A study of asphyxiated fetal sheep found that prolonged 
cerebral cooling started within 5.5 hours of birth is associated 
with neuronal rescue, but delaying the rescue to 8.5 hours 
results in a loss of the effect.8 Therefore, we recruited infants as 
early as possible, but set 8 hours as the maximum recruitment 
age.
Ethical approval was obtained from the University of 
Cape Town Medical Research Ethics Committee to conduct a 
randomised controlled study of selective cerebral hypothermia 
on 20 infants with HIE. However, after cooling the first 4 
babies, it was clear that repeated revisions to the technique had 
to be made and that the ice cap was not a satisfactory method 
of inducing selective cerebral cooling. If selective cerebral 
cooling was not being achieved then lower core temperatures 
would have to be used in those infants. The study was 
therefore stopped and the data and observations from the 4 
cooled infants are presented here in the form of a technical 
report. 
Method
Setting
This study was done in the neonatal units of Groote Schuur 
Hospital and Mowbray Maternity Hospital, Cape Town, South 
Africa.
Patients
From July 2000 to September 2001, infants were recruited 
during the first 8 hours of life when they met the following 
entry criteria: a gestational age of 37 or more weeks, a base 
deficit of 10 or more on arterial cord blood (or infant’s arterial 
blood within the first hour), an Apgar score of 6 or less at 
5 minutes after birth or the need for assisted ventilation at 
delivery, and signs of encephalopathy (with a score of at least 2 
on a previously validated scoring system).13 Written informed 
consent was obtained from parents or legal guardians.
Exclusion criteria were major congenital abnormalities, active 
bleeding, obvious sepsis, hypoxaemia requiring more than 
50% oxygen to maintain normal oxygen saturation and severe 
hypoglycaemia or electrolyte abnormality not responding to 
standard therapy.
Procedures
As soon as infants met the entry criteria, an insulated ice cap 
was applied and changed as required to maintain the rectal 
temperature (probe inserted 5 cm into the rectum) at 35 - 
35.5°C and a scalp temperature of 10 - 28°C. All infants were 
nursed in a closed, non-humidified incubator (Airshields, 
C100).
Temperature was regulated by servo-controlling the back 
skin temperature on supine infants. This location was chosen 
because it should approximate the rectal temperature but is 
technically easier to access. Scalp temperature over the anterior 
fontanelle, and nasopharyngeal and surface abdominal skin 
temperatures were also monitored. The probe position for 
nasopharyngeal temperature monitoring was estimated by 
measuring the nostril to ear tragus distance but in all cases this 
resulted in the tip of the probe protruding past the uvula, so it 
was withdrawn until it was palpable immediately above the 
uvula.
The temperature probes used in all infants were disposable 
thermistor probes, equivalent to the Yellow Springs 
International 400 series (Respiratory support Products, Inc., 
Smiths Industries Medical Systems, California, USA). Soft 
silicone size 8 French Foley catheter temperature probes with 
the same specifications as above were used (not inflated) in the 
rectum and nasopharynyx. Abdominal skin probes were fixed 
in position with a reflective disc supplied by the manufacturer 
and back skin and fontanelle probes were fixed in position 
using Tegaderm. Temperatures were documented every 5 
minutes at all sites except the back temperature which was 
monitored every 2 hours. 
The ice pack that was used for head cooling was a 12 × 12 cm 
freezable gel pack made by Penguin Manufacturers. This pack 
is normally used to keep vaccines cool in transit. The pack was 
covered with mutton cloth and then frozen around an empty 
2-litre cooldrink bottle to obtain a suitable curvature. The 
frozen ice pack was then secured onto the baby’s head over the 
anterior fontanelle. 
Following severe fluctuations in incubator and scalp 
temperatures in the first case (Fig. 1), the optimal timing and 
method of placement of the ice cap was refined with each 
subsequent case as shown in Table I. 
Restlessness and shivering were noticed in the first case 
treated. In the subsequent cases, phenobarbitone 20 mg/kg was 
routinely administered for sedation with the onset of cooling. 
If discomfort persisted, a second dose of phenobarbitone 
was administered and if discomfort persisted further, then 
morphine 0.03 mg/kg was given as a slow intravenous bolus. 
Apart from the cooling and additional sedation and analgesia, 
all infants received standard clinical care.
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Intravenous fluids were provided 
using potassium-free Neonatalyte at an 
initial volume of 50 ml/kg. Fluids were 
then adjusted on a daily basis as judged 
by the attending paediatrician. Clinical 
seizures occurred in 1 patient only and 
these were controlled with a second dose 
of phenobarbitone 20 mg/kg.
Cooling continued for 72 hours or 
until the encephalopathy had resolved, 
but the minimum duration of cooling 
was 48 hours. 
Statistical analysis
Temperature and vital signs data were 
analysed and graphically displayed 
using Statistica 6.0. 
Results
Baseline characteristics 
Birth weights ranged from 2 730 g to 
3 100 g and the base deficit in the first 
hour of life ranged from 12 to 16.5. 
Cerebral ultrasound was suggestive of 
cerebral oedema in 3 of the 4 infants at 
recruitment, but no infant manifested 
clinical seizures before cooling and all 
infants were breathing spontaneously in 
room air at the time.
Fig. 1. Temperature variation during cooling in case 1.
Table I. Cooling and re-warming strategies in the 4 cooled infants*
Case 1 Case 2 Case 3 Case 4
Age cooling commenced 5:24 5:50 5:30 7:20
Empiric phenobarbitone No Yes Yes Yes
pre-cooling
Layers of cloth over ice pack 1 1 1 2
Reflective covering over ice No Yes No No
cap
Ice cap change interval 2-hourly 2-hourly 2-hourly 3-hourly
Induction of cooling protocol Servo-control back Servo-control back Servo-control back Servo-control back
when ice cap is first applied temperature to 35.5°C temperature to 36.5°C temperature to 35.2°C temperature to 36.5°C and
for 10 minutes, then   reduce by 0.2°C every half
reduce by 0.2°C every   hour until 35.3°C
15 minutes until 35.5°C
Time to reach target rectal 00:45 2:00 4:00 3:00
temperature 
Duration of cooling 59:20 72:00 71:05 72:05
Warming protocol from the Servo-control back Servo-control back Servo-control back Servo-control back
time of removing ice cap temperature to 36°C temperature to 35.5°C for temperature to 35.2°C temperature to 35.5°C for 1
then increase by 0.5°C 1 hour. Increase by 0.5°C for 15 minutes, then hour. Increase to 36.5°C after
hourly until 37°C after 1 hour, then by increase to 35.5°C and 1 hour and increase to 37°C
0.2°C per hour until 37°C continue to increase by after another hour
0.5°C per 30 minutes 
until 37°C
Duration of re-warming 3:00 7:00 4:00 2:00
*Time shown as hours: minutes.
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Regional temperature variation
The target rectal temperature of 35 - 35.5°C was achieved in 
all cases except case 3 in which the mean rectal temperature 
was 34.7°C. The only case with an acceptably short time to 
target rectal temperature of under 1 hour was case 1. The rapid 
head cooling in this case and case 3 resulted in high incubator 
temperatures. The longer cooling time in case 3 was the result 
of manual manipulation of the incubator settings.
The incubator temperature varied by up to 7°C in cases 1 and 
3 and by up to 9°C in cases 2 and 4, but in cases 1 and 3, the 
incubator temperature rose above 37°C on several occasions. 
Fig. 1 shows the excessive regional temperature variations 
experienced by case 1 and this is representative of all cases, 
except case 4, where the maximum scalp temperature variation 
was reduced from 22°C to 12°C. The incubator temperature in 
this case only rose above 36°C to 36.5°C on one occasion.
The target scalp temperature was achieved in all infants 
except in case 4 where the mean nasopharyngeal temperature 
was 29.7°C. The use of a reflective covering on the ice cap in 
case 2 prevented adequate monitoring of the ice cap position 
and did not prevent incubator temperature fluctuation. 
Rewarming occurred in all infants in proportion to the speed 
with which the external heating was increased; the fastest 
rewarming time of 1°C per hour was achieved by increasing 
the desired temperature by the same rate, as was done in case 4.
Nasopharyngeal temperature monitoring
Although the trend of nasopharyngeal temperatures 
represented graphically in Fig. 1 suggests an increased 
nasopharyngeal-rectal temperature gradient during cooling, 
individual nasopharyngeal temperatures fluctuated rapidly 
and by several degrees over less than a minute in infants 
during times of agitation and rapid mouth breathing or crying.
Back temperature (in supine infants) versus surface 
abdominal temperature
Data from the 4 cooled infants were used to correlate insulated 
back temperatures and surface abdominal temperatures 
with rectal temperatures (Figs 2 and 3). The insulated back 
temperatures correlate much better with rectal temperatures 
than did the surface abdominal skin temperatures.
Cardiovascular and respiratory observations
The data of all groups were analysed collectively. During 
cooling, the respiratory rate dropped by an average of 19 
breaths per minute, the heart rate dropped by an average of 17 
beats per minute, and the mean arterial blood pressure rose by 
an average of 6 mmHg.  During rewarming, these parameters 
returned to the precooling state and at no time were the infants 
compromised by these changes.
Biochemical and haematological complications 
during cooling
Biochemical and haematological monitoring showed no 
significant irreversible adverse events due to cooling. In 
case 1, the serum sodium dropped to 125 mmol/l on day 2 
and blood sugar rose to 18 mmol/l because of inadvertent 
administration of excess intravenous fluid. Hypokalaemia was 
not encountered. Case 3 had transient hypoglycaemia. The 
metabolic acidosis on admission to the study progressively 
resolved during cooling and renal failure did not occur. The 
maximum prothrombin index of 2.5 on day 2 improved to 
normal limits by day 4 after treatment with intravenous 
vitamin K. No infant acquired infection during or after the 
study period.
Fig. 2. Mean rectal temperature versus mean back temperature during 
cooling.
Fig. 3. Mean rectal temperature versus mean surface abdominal skin 
temperature during cooling.
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Physical and short-term neurological outcomes in 
cooled infants 
There were no local side-effects from the ice packs. Two of 
the cooled infants progressed to moderate encephalopathy 
but there were no neurological abnormalities at the time of 
discharge in any of the infants. Full feeds were established 
between day 5 and day 8.
Discussion
This method of cooling is not simple and there were large 
fluctuations in regional temperatures. The constant vigilance 
required to prevent further variation in incubator temperature 
and the repeated changing of the ice packs was labour 
intensive. The high incubator temperatures were thought to be 
due to the excessive cooling effect of the ice cap, coupled with 
the use of external heating to maintain systemic temperature at 
35 - 35.5°C. The strategy of insulating the pack, making it less 
cool and at the same time prolonging the thaw time, resulted 
in lower incubator temperatures and less scalp temperature 
fluctuations but average scalp temperatures were higher than 
desired. Fluctuations in scalp temperature will not be noticed 
if scalp temperature is not measured frequently. This is an 
important finding because large variation in temperature 
causes variable perfusion and this could potentially exacerbate 
cerebral injury.
Although the exact depth of cooling required to achieve 
neuroprotection is not known, a review of several studies14 
suggests that the optimal brain temperature to achieve 
neuroprotection with minimal side-effects is 32 - 34°C. 
Brain temperature during cooling has been related to scalp 
temperature using numerical modelling15 which  predicts that 
a scalp temperature of 24°C with a core temperature of 34°C 
results in a temperature gradient of 32 - 28°C across the cortex. 
Therefore, in the first two cases with mean scalp temperatures 
of 21°C, there was probably significant selective cerebral 
cooling, but the scalp temperatures of 27 and 29.7°C in cases 3 
and 4 respectively, suggest that selective cerebral cooling was 
not achieved in these cases. If significant selective cerebral 
cooling is not occurring, then deeper core temperatures of 33 - 
34°C must be achieved with whole-body cooling.
Gunn et al.10 used nasopharyngeal temperatures to infer 
cerebral cooling. However, we found that the nasopharyngeal 
temperature varied greatly with mouth breathing and therefore 
has little value in spontaneously breathing infants. 
Gunn et al.10 used surface abdominal skin as a site to servo-
control temperature of cooled infants but commented that 
manual adjustment was required intermittently. We also 
found that the surface abdominal temperature varied greatly 
and was subject to environmental influence. The covered 
back temperature showed close correlation with the rectal 
temperature and in future studies we suggest that this site 
could be used to servo-control temperature instead of rectal 
temperature.
The infants that we cooled frequently became agitated 
and exhibited shivering. In animal studies, unsedated cooled 
piglets had cortisol levels three times higher than those of 
their normothermic counterparts16 and neuroprotection was 
not successful. This supports our finding that sedation and 
analgesia are necessary during induced hypothermia.
In summary, the salient lessons and recommendations that 
can be derived from the four infants studied are as follows:
1.  Solid ice cap application is not recommended for inducing 
selective cerebral hypothermia. Increased insulation of the ice 
cap can be used to successfully induce whole-body cooling 
but the fluctuation in incubator and scalp temperatures is still 
not ideal. However, there will probably be less fluctuation 
if external heating is reduced by accepting a target core 
temperature of 33 - 34°C which has recently been shown to 
be safe.17-19 A more uniform method of head or whole-body 
cooling would be preferable if it were available and simple to 
use.
2.  The ice cap did not result in local complications.
3.  Mild systemic cooling did not result in significant 
systemic or biochemical complications.
4.  Nasopharyngeal temperature monitoring is not an 
accurate reflection of brain temperature in spontaneously 
breathing infants.
5.  The superficial abdominal skin temperature was not a 
reliable indicator of core temperature, but the covered back 
temperature closely follows the core temperature and this 
site may be used as a less invasive alternative to deep rectal 
temperature monitoring.
6.  Sedation and analgesia to control discomfort should be 
given to infants with induced hypothermia to reduce stress and 
decrease shivering.
The current international consensus opinion of the 
National Institute of Child Health and Human Development 
recommends that results from outstanding trials should be 
awaited and reviewed before hypothermia becomes a standard 
of care for infants with HIE, and that care should be taken to 
prevent inadvertent overheating of these infants.20 We support 
this statement. If infants with HIE are cooled, parental consent 
should be sought and there should be a careful audit of the 
intervention, bearing the above lessons in mind.
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Risk behaviour can be defined as behaviour that increases 
one’s risk of adverse outcomes in the short or long term, in 
the psychological, social or physical domains. Several national 
studies have documented prevalence rates of risk behaviours 
among South African adolescents, including national 
household surveys conducted by the Human Sciences Research 
Council in 20021 and 2005,2 a national household survey of 
15 - 24-year olds,3 and a national survey of risk behaviour 
among youth in grades 8 - 11 in public high schools.4 The 
present report compares risk behaviour of grade 8 students in 
Cape Town across two time points, 1997 and 2004. This time 
period is important, as one would expect the consequences 
of South Africa’s transition to a democratic dispensation to 
become evident in these years. It also coincides with a period 
of rapid advance of the HIV epidemic, with a corresponding 
increase in the extent of AIDS prevention activities. Against 
this background, it is crucial to know whether these profound 
social changes were accompanied by changes in levels of risk 
behaviour of high-school students. 
Methods
The data reported in this paper were derived from two studies, 
conducted in 1997 and 2004. While selected prevalence rates 
from the 1997 study have been reported previously,5-7 the 
prevalence rates from the 2004 study are reported for the first 
time in this paper.      
Populations and samples
In both 1997 and 2004, the study population was grade 8 
students attending public schools in Cape Town. 
In 1997, we stratified the schools by postal code groupings 
since these groupings are relatively homogeneous in terms 
of factors such as social class, racially defined social group, 
language and culture. We selected 39 schools such that the 
proportion of schools in a selected stratum was directly 
proportional to the number of students in that stratum. The 
selection probability of a school was proportional to the 
number of students in that school. We selected 40 students 
from the combined class lists of two randomly selected grade 8 
classes.
The 2004 sample consisted of 15 schools randomly selected 
from the 39 schools selected in 1997 using simple random 
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Objective. To compare prevalence rates of selected risk 
behaviours and age of first intercourse of grade 8 students in 
Cape Town between 1997 and 2004.
Design. Cross-sectional surveys in 1997 and 2004. Survival 
analysis was used to estimate the cumulative incidence of first 
intercourse. The log-rank statistic was used to compare the 
survival distributions. When comparing data from the two 
studies we used a logistic regression model with the factors 
year, race and age group to test the difference in reported risk 
behaviours between 1997 and 2004 within each gender.             
Setting. Public high schools in Cape Town.
Subjects. Multistage cluster samples of 1 437 and 6 266 grade 8 
students in 1997 and 2004 respectively.
Outcome measures. Ever having had sexual intercourse; for those 
that had, whether any method was used to prevent pregnancy 
or disease at last intercourse, and (if so) what was used; use of 
tobacco, alcohol and marijuana; violence-related behaviours; 
and suicidal behaviour.
Results. There was a significant delay in first intercourse in 2004 
compared with 1997. For males, levels of condom use were 
lower in 2004 than in 1997, while for females levels of injectable 
contraceptive use were lower. There were significant increases 
in past month use of cigarettes for males and marijuana for 
both genders. Rates of perpetration of violence behaviour 
remained stable or decreased from 1997 to 2004, while the rate 
of suicidal behaviour for males increased. 
Conclusions. School-based interventions that address sexual 
risk behaviours should be expanded to include other risk 
behaviours.
S Afr Med J 2006; 96: 982-987.
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sampling. All grade 8 students were selected to participate 
in the study. Each of these selected schools was matched to 
another school on a range of demographic characteristics 
(student population size, socially defined racial group of 
students, language of instruction, geographical area in which 
the school was located and the school fee (as a proxy for 
socio-economic status)). Fifteen matched pairs were formed 
as a result of this for use in an intervention study of an AIDS 
prevention strategy. Two pairs of schools were excluded 
from the study owing to difficulties in obtaining consent to 
participate in the intervention study.
Procedure
The selected students completed a questionnaire during a 
normal school period. The seating was arranged to minimise 
the risk of students seeing the responses of their classmates. 
No school staff were present during the administration of the 
questionnaire. 
In 1997 the questionnaire was in paper-and-pencil format. 
In 2004 it was administered using personal digital assistants 
(PDAs). We have compared the test-retest reliability of the 
electronic questionnaires with paper-and-pencil questionnaires, 
and found that it was similar.8
In both years, after obtaining permission from the Western 
Cape Education Department and the participating schools, we 
sent a letter to parents at all participating schools to introduce 
the study. If a parent objected to their child participating in the 
study, they were asked to convey this by contacting the school 
or the research team or completing a declination form attached 
to the letter and returning it to the evaluation co-ordinators. 
All participating learners signed an assent form agreeing to 
participate.
Instrument
The instrument used in the 1997 study had been used in 
previous studies9,10 and has been subject to extensive pilot 
studies in small groups and classrooms. In addition, the test-
retest reliability of the items has been documented, and found 
to be at least satisfactory.11,12 Finally, there is considerable 
evidence of the validity of the items, since they have been 
shown to be associated with a large number of relevant 
constructs.13
The items in the 2004 questionnaire addressing violence 
(including suicidality) were identical to those in the 1997 
questionnaire. However, the items addressing sexual behaviour 
and substance use differed slightly in format, in that in 1997 
they had stem questions followed by a set of contingent 
questions. For example, in 1997 the students were asked ‘Have 
you ever had sexual intercourse? This means intimate contact 
with someone of the opposite sex during which the penis 
enters the vagina (female private parts)’. Students answering 
positively were asked a number of further questions, for 
example whether they or their partner had used anything to 
prevent pregnancy or disease. However, in 2004 all students 
were required to answer all questions. If a question involved an 
issue that was not applicable to a particular student, they were 
given the option of indicating this (for example, a question 
involving condom use would have an option indicating that 
the student had not had sexual intercourse). Likewise, in 1997, 
for the items involving substance use, the students were asked 
if they had ever used the substance in question, and then asked 
contingent questions if they had done so. One such contingent 
question inquired about how many days in the previous month 
the substance had been used. In 2004, the respondents were 
asked whether they had used each of a series of substances 
in the previous month. For the purposes of this report, the 
1997 responses were recorded to form a dichotomous variable 
indicating use in the previous month or not.                               
Analysis
For purposes of analysis the schools sampled in 2004 as well as 
those matched were considered to be a random sample from 
the public schools in 2004 and comparable to the sample drawn 
in 1997.
The pooled data for 1997 and 2004 were used for the 
estimation of the prevalence for the various characteristics by 
gender and year. An indicator variable for the 65 schools was 
created. We used the Stata programme to calculate proportions 
and 95% confidence intervals (CIs) by gender and year taking 
the sampling of schools at the first stage into account. No 
sampling weights were used since no ‘sensible’ weights can be 
calculated for the 2004 sample. For contingent questions, we 
calculated the prevalence rates for the number of students who 
had engaged in the activity to the number of students who 
answered affirmatively to the main question. 
For comparing the crude prevalence of the gender and 
year combinations for a specific characteristic, one can use 
the reported 95% CIs. If the CIs do not overlap, there is a 
significant (p < 0.05) difference between the groups. If they 
overlap to the extent that the point estimate of one group is 
contained within the CI of the other group, the two estimates 
are not significantly different (p > 0.05). If the CIs overlap, 
but not to the extent that the point estimate of one group 
is contained within the CI of the other group, no definite 
conclusion can be made and a formal test has to be performed. 
For this purpose a formal comparison was done for a specific 
characteristic between the prevalences for 1997 and 2004 for 
each gender using a logistic regression model with adjustment 
for the factors age group and race. The clustering due to 
the sampling of schools was taken into account as well. The 
gender-specific analysis was done because gender was an 
important differentiating factor in the 1997 study.6
We used survival analysis to estimate the cumulative 
incidence over a limited age interval of the event first 
intercourse by gender and year. This approach enabled us 
to provide estimates of the age of first intercourse that were 
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not biased by the current ages of the study participants. The 
reported age at first intercourse was used as the time to the 
event in the survival analysis. Students who had not yet 
experienced sexual intercourse were censored at their reported 
current age. The Kaplan-Meier product limit method was 
used to estimate the incidence curves and the corresponding 
confidence limits. The log-rank statistic was used to compare 
the survival distributions.                  
Results
The details of the samples are presented in Table I, and the 
results of the survival analysis of age of first intercourse are 
presented in Table II and Fig. 1. For both males (C2 = 21.97, 
p < 0.00) and females (C2 = 44.93, p < 0.00), there was a signifi-
cant delay in first intercourse in 2004 compared with 1997.  For 
example, in 2004 12.9% of male students aged 14 years had 
experienced their sexual debut whereas the equivalent figure 
in 1997 was 17.4%. The duration of the relative delay was about 
1 year. Furthermore, for both years there was a significant 
delay in first intercourse for females compared with males. 
The protection used by students who had experienced 
intercourse is presented in Table III. For use of any method, 
females were significantly more likely to use protection than 
males in 1997. However, in 2004 the converse finding was 
obtained, with males being more likely to use protection than 
females. For both males and females, use of protection was 
significantly less likely in 2004 compared with 1997. In both 
1997 and 2004, males were significantly more likely to use 
condoms than females. Males were significantly less likely to 
use condoms in 2004 compared with 1997, while for females 
Table I. Demographic description of the samples in 1997 
and 2004*
         1997        2004
    (N = 1437)  (N = 6266)
   N % N %
Gender    
   Males   625 43.5 3 026 48.3
   Females  812 56.5 3 240 51.7
SDRG     
   Black   399 28.5 2 314 42.0
   Coloured  737 52.6 2 214 40.2
   Indian   9 0.6 34 0.6
   White   256 18.3 908 16.5
   Other    0 0.0 37 0.7
Age category     
   13 years or less  514 35.2 1 752 20.0
   14 years  542 37.1 2 761 44.5
   15 years  231 15.8 1 225 19.7
   16 years or less   174 11.9 983 15.8
* Column totals for demographic categories are less than the total sample sizes owing 
to missing values for these categories.
SDRG = self-denoted race group.
Table II. Estimated cumulative incidence of debut sexual intercourse
     Percentage who have had intercourse (95% confidence interval)
     2004      1997
Age (years)  Males   Females   Males   Females
10   2.7 (2.1 - 3.4)  0.1 (0.1 - 3.5)  4.8 (3.0 - 6.3)  0.3 (0.1 - 0.9)
11   4.6 (3.8 - 5.4)  0.2 (0.1 - 0.4)  5.7 (4.1 - 7.8)  0.4 (0.1 - 1.2)
12   8.0 (7.1 - 9.2)  0.6 (0.4 - 0.9)  8.1 (6.2 - 10.6)  0.8 (0.3  - 1.7)
13   10.8 (9.6 - 12.1)  1.5 (1.1 - 2.0)  12.8 (10.4 - 15.8)  2.5 (1.6 - 3.9)
14   12.9 (11.7 - 14.3)  2.9 (2.3 - 3.6)  17.4 (14.5 - 20.9)  7.5 (5.6 - 10.0)
15   17.1 (15.4 - 19.0)  6.6 (5.3 - 8.2)  27.9 (23.1 - 33.5)  18.5 (14.2 - 23.9)
16   19.6 (17.4 - 22.0)  14.5 (11.6 - 18.2)  37.3 (30.3 - 45.4)  29.8 (22.3 - 39.0)
17   22.6 (19.5 - 20.4)  19.7 (15.2 - 25.4)  37.3 (30.3 - 45.4)  34.8 (24.1 - 48.5) 
Table III. Estimated prevalence (95% confidence interval) for protection used at last intercourse for students who had 
experienced sexual intercourse
    Males      Females
  1997  2004    1997  2004  
  (N = 133)  (N = 815)    (N = 83)  (N = 326)
  % (CI)  % (CI)  p  % (CI)  % (CI)  Adjusted p*
Any method 50   37.9  0.01  64.6  23.8  0.00
  (40.5 - 59.5) (33.9 - 42.1)   (53.6 - 74.2) (20.1 - 27.9)
Condom  67.2   44.2  0.00  34.6  35.1  0.96
  (59.4 - 74.1) (40.2 - 48.3)   (21.8 - 50.0) (30.4 - 40.0)
Oral contraceptive 8.6   11.7  0.17  7.6  7.1  0.79  
  (5.0 - 14.5) (9.1 - 14.8)   (3.7 - 15.0) (4.8 - 10.3)
Injection  9.5   8.0  0.10  53.1  17.7  0.00
  (4.4 - 19.2) (6.3 - 10.1)   (39.0 - 66.7) (12.8 - 24.0)
*p-value from gender-specific logistic regression model of protection indicator on year adjusted for age group and socially defined racial group.
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there were no significant differences in condom use between 
the two years. Females were significantly more likely than 
males to use injections in both years. While there was no 
significant difference in the proportion of males whose partners 
used injections between the two years, there was a large and 
significant decline in the proportion of females who used them 
(from 53.1% to 17.7%). There were no significant differences 
between the genders or the years in the proportion who used 
oral contraceptives.    
In terms of substance use (Table IV), we observed significant 
increases for past month use of cigarettes for males and 
marijuana for both males and females. There were no 
significant differences for past month use of alcohol. In terms 
of violence-related behaviours, there were significant increases 
for carrying a knife to school to be used as a weapon (males 
and females) and causing serious damage to property (males 
only). However, there were significant decreases for going out 
at night beyond the neighbourhood and walking home alone 
(both genders), stealing (both genders), bullying (females only) 
and being bullied (both genders). There was a significant and 
large increase in suicidal behaviour for males (from 7.0% to 
20.7%), but no difference for females.              
Discussion
We found that there was a significant and substantial delay 
in first intercourse from 1997 to 2004. There are two possible 
explanations for this change. First, it could be due to the effects 
of intervention efforts that were implemented in these years. 
Second, the effects of the HIV epidemic may have become 
more evident in these years, as more people display symptoms 
of HIV infection or die. This could contribute to behaviour 
change through making it more difficult to deny the existence 
of the disease or to attribute it to other groups.14 Whatever 
the reason for the change, it is encouraging that age of sexual 
debut among grade 8 students in Cape Town occurred later in 
2004 than in 1997, especially given the relatively short period of 
time involved. However, these findings are not consistent with 
the trends inferred from the Human Sciences Research Council 
household surveys, which concluded that in 2005 young 
people aged 15 - 24 years were engaging in sexual intercourse 
at a younger age than in 2003 or 2002.2
The findings for use of protection against pregnancy and 
disease were, however, discouraging. The proportion of 
both males and females who used any form of protection 
declined significantly between 1997 and 2004. One possible 
explanation for this finding is that young people might have 
been more likely to have sexual encounters in the context of 
longer and more stable relationships in 2004 compared with 
1997. This is relevant for protection use, since young people 
may be less likely to use protection in such relationships. If 
further research confirms this explanation, the implication for 
prevention activities is that the necessity for protection should 
be emphasised, whether the relationship in which the sexual 
activity takes place is ongoing or not. 
For males, the reduction in the proportion who used 
contraception between 2004 and 1997 can be attributed to 
a reduction in the proportion who used condoms, since 
the proportion whose partners used oral or injectable 
contraceptives remained stable in this time period. The 
reduction in the proportion who used condoms implies that 
increased numbers were at risk both of contracting sexually 
transmitted infections (including HIV infection) and of 
impregnating their partners. This finding contradicts data from 
the Human Sciences Research Council national household 
surveys which show a substantial increase in reported condom 
use at last sexual encounter among young men (and young 
women) aged 15 - 24 years between 2002 and 2005.2 However, 
for females the decline in contraception use can be attributed 
to a large reduction in the proportion who used injectable 
contraceptives (from 53.1% to 17.7%). There was no change 
in the proportion who used oral contraceptives, or in the 
proportion whose partners used condoms. The reduction in 
the proportion who used injectable contraceptives may be 
a consequence of personnel at clinics encouraging the use 
of condoms owing to their beneficial effects on risk of HIV 
infection, even though the policy is that ‘dual protection’ 
(against risk of sexually transmitted infections and pregnancy) 
should be promoted. Another explanation is that concern about 
the adverse consequences of injectable contraceptives has 
resulted in decreased demand by service users and decreased 
promotion by service providers. Whatever the explanation for 
the decrease in use of injectable contraception, it is a source of 
concern that this decrease has placed large numbers of young 
women at risk for pregnancy. 
The rate of recent tobacco use increased for males only, 
and there were no significant differences for recent alcohol 
use (although there was a trend (p = 0.08) for the rate among 
females to decrease). There were significant and large increases 
in the rates of marijuana use for both males (from 3.1% to 
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17.2%) and females (from 1.9% to 5.2%). Furthermore, the rates 
in 1997 were almost double those observed in a 1990 study that 
included grade 8 students.10 Although the sampling strategies 
differed in the two studies, both studies aimed to produce 
samples that were representative of students in Cape Town 
in the selected grades. There is therefore robust evidence of a 
secular trend of an increase in marijuana use among grade 8 
students in Cape Town from 1990 to 2004. This may be due to 
more vigorous enforcement of laws that aim to reduce drug use 
in developed countries such as the USA, or increased access 
to cannabis because the borders have become more open in 
recent years. The effects of an increase in marijuana use will be 
amplified by the current epidemic of crystal methamphetamine 
(‘tik’) in Cape Town. Urgent steps are necessary to address use 
of illicit drugs among young people in Cape Town.
The rates of stealing, exposure to bullying as perpetrator 
or victim, and involvement in physical fights decreased or 
remained stable for both males and females in the period 
under study. However, the proportion who had gone out at 
night beyond their neighbourhood and walked home alone 
decreased for both genders. This could reflect an increased 
sense of vulnerability to interpersonal violence. The increased 
rate of carrying a knife to school to be used as a weapon could 
also reflect such increased vulnerability, in that the young 
people may have carried knives to protect themselves if 
attacked.
There was a large increase in the proportion of boys who had 
attempted suicide in the previous year (from 7.0% to 20.7%), 
while the rate for girls remained stable. When comparing the 
1997 data with those from the 1990 study cited above,10 there 
Table IV. Estimated prevalence (95% confidence interval) for non-sexual risk behaviours for all students
          Males      Females
  1997  2004    1997  2004  
  (N = 625)  (N = 3 026)   (N = 812)  (N = 3 240)  
  % (CI)  % (CI)  Adjusted p* % (CI)  % (CI)  Adjusted p*
Smoke a whole 23.0     31.5  0.00  21.3  18.2  0.11
cigarette (4 weeks) (18.2  -  27.9) (28.5 - 34.6)   (15.2 - 27.4) (14.5 - 21.9)
Use alcohol 
(including wine 
and beer), other 
than a few sips 22.0   25.9  0.23  18.0  14.8  0.08
(4 weeks)  (17.3 - 26.8) (23.1 - 28.7)   (13.4 - 22.6) (13.0 - 16.7)
Smoke marijuana 3.1  17.2  0.00  1.9  5.2  0.01
(4 weeks)  (1.7 - 4.5)  (13.8 - 20.6)   (0.9 - 2.9)  (3.7 - 6.6)
Carry a knife at 
school to be used 
as a weapon 9.7  18.0  0.01  1.3  4.6  0.00
(4 weeks)  (6.9 - 12.5) (14.2 - 21.7)   (0.4 - 2.1)  (2.9 - 6.2)
Go out at night 
beyond the   
neighbourhood 
and walk home 37.7  29.0  0.00  17.1  12.1  0.00
alone (4 weeks) (33.3 - 42.0) (26.5 - 31.3)   (13.9 - 20.2) (10.2 - 14.0)
Stealing anything 
from anybody 37.9   32.5  0.04  23.2  15.6  0.00
(12 months) (33.3 - 42.5) (29.2 - 35.7)   (19.4 - 26.9) (13.5 - 17.6)
Cause serious 
damage to property 14.4  22.7  0.00  6.8  7.8  0.75
(12 months) (11.5 - 17.2) (20.8 - 24.7)   (4.6 - 9.0)  (6.5 - 9.0)
Bully anybody at 28.4  26.2  0.19  15.7  12.6  0.01
school (12 months) (23.6 - 33.3) (24.4 - 28.1)   (12.7 - 18.7) (11.0 - 14.3)
Been bullied at 41.1  31.4  0.00  30.3  15.7  0.00
school (12 months) (35.8 - 46.4) (29.0 - 33.7)   (25.6 - 34.9) (14.4 - 16.9)
Been involved in 
any physical fights 36.4  32.8  0.25  16.9  15.9  0.41
(12 months) (31.8 - 41.1) (30.3 - 35.2)   (13.8 - 19.9) (14.1 - 17.7)
Try to put an end 
to one’s life 7.0  20.7  0.00  16.9  16.9  0.67
(12 months) (4.6 - 9.4)  (17.3 - 24.1)   (13.2 - 20.6) (14.6 - 19.2)
*p-value from gender-specific logistic regression model of non-sexual risk behaviour indicator on year adjusted for age group and socially defined racial group.
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were no significant changes for either gender. An analysis of 
nationally registered mortality data showed an increase in the 
suicide rate for young white males only from 1968 to 1990.15
However, the increase for males in the current study was not 
evident only for white males, since socially defined racial 
group was included as a covariate in the multiple logistic 
regression analyses. It is an urgent research priority to ascertain 
whether this increase is also present in other age groups and 
other places in South Africa, and to identify the reasons for 
the increase. Such reasons are necessarily applicable only to 
males.                                                                            
It is important to mention the limitations of the study. First, 
it was limited to students who were present at school on 
the day the study was undertaken, thus excluding dropouts 
and absentees who may have higher rates of risk behaviour.9
However, for this to bias the findings about secular trends, 
the relationship between risk behaviour and dropout or 
absenteeism would need to be different between the two time 
periods. There is no reason to think that this might be the case. 
Also, the data for those who attend school are applicable for 
school-based interventions. Second, the study was confined 
to grade 8 students attending public high schools in Cape 
Town, which limits the extent to which the findings can be 
generalised to other populations. Third, the study relied on 
self-report data. Although we went to great lengths to ensure 
anonymity and confidentiality, it is possible that the data are 
biased, probably in the direction of providing falsely low 
prevalence estimates for the risk behaviours. Again, for this 
to bias the findings about secular trends, the extent and/or 
direction of the bias would need to vary between the two time 
periods, and again there is no reason to think that this might be 
the case. Finally, there were some methodological differences 
between the two studies. A different means of data collection 
was employed at the two stages. In 1997, we collected data 
using paper and pencil questionnaires, while in 2004 we used 
PDAs. However, our pilot work concluded that there were no 
significant differences in the prevalence rates obtained using 
the two methods.8 In addition, if this were a relevant bias, one 
would expect that the differences between the time periods 
would all be in the same direction, which was not the case. 
Other methodological differences between the studies include 
the differences in question format and the absence of weighting 
in the 2004 study.        
In conclusion, the study confirms that large numbers of 
grade 8 students in Cape Town engage in risk behaviour. It is 
necessary to replicate the findings regarding secular trends, 
as they may be attributable to the methodological differences 
between the studies mentioned above. However, if they are 
valid, there are some positive findings regarding secular 
trends for postponement of sexual debut and involvement in 
behaviours that are associated with interpersonal violence. 
These findings indicate that it is possible for risk behaviour 
to change in a relatively short period of time. However, the 
rates of selected risk behaviours among boys and/or girls 
changed in a direction that is associated with increased 
risk of adverse outcomes, such as use of protection against 
pregnancy of sexually transmitted infections, tobacco use, 
marijuana use, and suicidal behaviour. There are a number of 
school-based interventions in Cape Town high schools that 
have as their main aim to reduce the prevalence of sexual risk 
behaviours, including two cluster randomised control trials,16,17
the loveLife groundBREAKER intervention,18 and a peer 
education intervention18 that is funded by the Department of 
Health in the Western Cape and implemented by various non-
profit organisations. There is an urgent need to disseminate 
interventions that effectively reduce sexual risk behaviour. 
In addition, such interventions should increase their scope 
to address other the risk behaviours (such as substance use, 
interpersonal violence and suicidal behaviour) with which 
involvement in sexual risk behaviour is correlated and with 
which it shares common aetiological roots.19,20   
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The World Health Organization (WHO) and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) launched their 
‘3 by 5’ initiative in December 2003. The principal aim was 
to mobilise the world to provide highly active antiretroviral 
therapy (HAART) to 3 million people living with HIV/AIDS in 
low- and middle-income countries by the end of 2005.1 By June 
2005 approximately 1 million people were receiving HAART in 
these countries, giving an estimated average coverage rate of 
15%.  Of an estimated 600 000 children in sub-Saharan Africa 
who required HAART, less than 5% were receiving therapy.2
Consequently, the United Nations Children’s Emergency Fund 
(UNICEF) along with the WHO and UNAIDS have begun 
to mobilise global forces to intensify perinatal prevention 
programmes, and extend care, particularly in the provision 
of co-trimoxazole prophylaxis to HIV-exposed children and 
HAART to all infected children in poor countries.3
From 1996 onwards triple combination antiretroviral (ARV) 
therapy has been used to treat HIV-infected children.4,5 Since 
then a large body of research has been published attesting 
to the benefits of HAART in children. Although in general 
virological control has been more difficult to achieve in 
children compared with adults, the risks of progression to 
end-stage disease or AIDS and death have been significantly 
attenuated in children treated with HAART.4,5 Furthermore, 
improvements in growth and body composition parameters, 
reduced frequency and severity of infectious complications, 
decreased hospitalisation rates and reversal or prevention 
of organ-specific damage have been achieved.6-9 Long-term 
survival is possible and some perinatally infected children 
have already reached their second or third decade of life.10,11
Research has also documented some concerns associated with 
HAART including the overall negative impact of HIV infection 
on quality of life among children, emergence of viral resistance, 
long-term metabolic complications, and the challenges of 
managing these problems.10,12
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Objective. To describe the response of children during their first 
year on highly active antiretroviral therapy (HAART). 
Design. Retrospective, descriptive.
Setting. Tertiary, referral hospital.
Subjects. All HIV-infected children commenced on HAART 
from 1 August 2002 until 31 December 2004.
Outcome measures. Children were retrospectively restaged 
using the WHO 4-stage clinical classification and CDC 
immunological staging system. After commencing HAART, 
patients were assessed at monthly intervals for the first 6 
months and thereafter mostly 3-monthly. Baseline and 6-
monthly CD4 counts and viral loads were performed.   
Results. Of 409 children commenced on HAART, 50.6% were 
< 2 years old, 62.7% had severe clinical disease and 76.6% had 
severe immune suppression. After 1 year, 65.8% were alive and 
continued HAART at the hospital, 11.2% had been transferred 
to another antiretroviral site, 15.4% had died, 4.6% were lost 
to follow-up and treatment had been discontinued in 2.9%. 
Kaplan-Meier survival estimate for 407 children at 1 year was 
84% (95% confidence interval (CI) 80 - 87%). On multivariate 
analysis, survival was adversely affected in children with 
WHO stage 4 v. stage 2 and 3 disease (adjusted hazard ratio 
(HR): 5.26 (95% CI 2.25 - 12.32), p = 0.000), age < 12 months 
(adjusted HR: 2.46 (95% CI 1.48 - 4.09), p = 0.001) and CD4 
absolute count (per 100 cell increase) (adjusted HR: 0.93 (95% 
CI 0.88 - 0.98), p = 0.013). In a separate multivariate model 
including only children with an initial viral load (N = 367), 
viral load r 1 million copies/ml (adjusted HR: 1.84 (95% CI 
1.03 - 3.29)) and taking a protease inhibitor (PI)-based regimen 
(adjusted HR: 2.25 (95% CI 1.10 - 4.61)) were additionally 
independently associated with poorer survival; however, 
young age was not a significant predictor of mortality, after 
adjusting for viral load (p = 0.119). After 1 year of HAART 
184/264 (69.7%) of children had a viral load < 400 copies/ml. 
Comparative analysis showed significant improvements in 
growth, immunological status and virological control. 
Conclusion. HAART can improve the health of many HIV-
infected children with advanced disease, including those aged 
less than 2 years in resource-limited settings. 
S Afr Med J 2006; 96: 988-993.
ORIGINAL ARTICLES
989
September 2006, Vol. 96, No. 9  SAMJ
Several studies on paediatric ARV treatment programmes 
in middle- and low-income countries have documented 
favourable responses to HAART.13-16 At Red Cross War 
Memorial Children’s Hospital (RCH) a donor-funded ARV 
treatment programme for children was started in August 2002. 
Initial experience of this programme was reported on in 2004.17
Between February and November 2004, after the Western 
Cape province of South Africa began providing HAART to 
public sector patients, the donor-funded programme was 
fully integrated with the provincial programme. At the end 
of March 2006 RCH was therefore one of 37 accredited public 
sector institutions in the Western Cape managing children on 
HAART. At the time, 16 300 patients were receiving HAART 
in the province of whom 2009 (12.3%) were children. In this 
report we describe the response of children during their first 
year on HAART at our institution.
Methods
This retrospective study describes a public sector ARV 
treatment programme for HIV-infected children. The study 
took place at Red Cross War Memorial Children’s Hospital, 
a tertiary referral hospital affiliated to the University of 
Cape Town. All children who started treatment between 1 
August 2002 and 1 December 2004 were included. The study 
documented the outcomes of children during their first year on 
HAART. The Research Ethics Committee of the University of 
Cape Town approved the study.
Children were selected to start HAART according to 
established clinical and immunological criteria. The first 122 
children were enrolled according to criteria derived from 
the Paediatric European Network for the Treatment of AIDS 
(PENTA) recommendations. Briefly, children with Centers 
for Disease Control (CDC) clinical category C or immune 
category 3 disease and those with CDC clinical category B 
disease plus a low CD4 percentage (< 20% if < 12 months 
old or < 15% if > 12 months old) qualified for treatment and 
were considered for enrolment.18 The remaining 287 children 
were enrolled according to criteria derived from the WHO’s 
2003 recommendations for children. Children with modified 
WHO clinical stage 2 or 3 disease or a low CD4 percentage 
irrespective of disease stage (< 20% if < 18 months old or < 
15% if > 18 months old) qualified for HAART.19 In addition to 
the clinical and/or immunological criteria all children were 
required to have an identifiable caregiver who could take 
responsibility for the administration of the medication.
Triple combination ARV therapy comprising of 2 nucleoside 
reverse transcriptase inhibitors (NRTIs) plus either a non-
nucleoside reverse transcriptase inhibitor (NNRTI) or 
a protease inhibitor (PI) was administered according to 
conventional paediatric dosing recommendations.20 The 
choice of individual drugs was determined by funding 
constraints, availability of home refrigeration required to 
store temperature-sensitive drug formulations, and previous 
exposure to perinatal nevirapine. Children who had been 
exposed to perinatal nevirapine were given a PI-based regimen 
in keeping with the national treatment guidelines of South 
Africa.21 The monitoring plan included monthly clinical 
assessments for the first 6 months of therapy and thereafter 
mostly 3-monthly reviews, baseline and 6-monthly CD4 counts 
and viral loads (due to financial constraints, the viral load at 6 
months was omitted in the first 122 children unless they were 
enrolled in parallel research studies), and regular biochemical 
and haematological evaluations. 
For the purpose of this analysis, all children were 
retrospectively re-staged at the time of starting HAART 
according to the latest WHO 4-stage clinical classification and 
the CDC immunological staging system.22,23  Weight-for-age, 
height-for-age and weight-for-height z-scores were calculated 
using EpiInfo 2000, version 1.0, Division of Surveillance and 
Epidemiology, CDC, Atlanta, Georgia. Moderate underweight, 
stunting and wasting were defined as weight-for-age z-score 
(WAZ) < -2, height-for-age z-score (HAZ) < -2 and weight-for-
height z-score (WHZ) < -2 respectively. Severe underweight, 
stunting and wasting were defined as WAZ < -3, HAZ < 
-3 and WHZ < -3 respectively.24 Data were analysed using 
Stata version 8.0, College Station, Texas, USA and StatsDirect 
software, version 2.5.5, 2006, Cheshire, UK. The probability of 
survival was determined using Kaplan-Meier analysis and log-
rank tests were used to compare survival times between strata. 
The Cox proportional hazards model was used for multivariate 
analysis. Patient characteristics found to be associated with 
mortality (p < 0.1) on univariate analysis were included in the 
multivariate model, and removed by a backward selection 
procedure if p > 0.05. Separate models were estimated for all 
children, and on the subset on whom initial viral load was 
measured. The regimen variable (PI v. NNRTI) was then added 
to both models to assess whether regimen was independently 
associated with survival. The Wilcoxon signed ranks test was 
used to compare continuous data. The chi-square test was used 
to compare categorical data. A p-value of < 0.05 was regarded 
as statistically significant.
Results
By the end of December 2004, 409 children had been 
enrolled on the ARV treatment programme. The median 
age (interquartile range) at enrolment was 23 months (8.9, 
54.6), 207/409 (50.6%) were less than 24 months old and the 
female-to-male ratio was 182:227. Baseline clinical staging was 
available for 407 children: 3 (0.7%) had WHO stage 2 disease, 
149 (36.6%) WHO stage 3 disease and 255 (62.7%) WHO stage 4 
or advanced clinical disease. CD4 percentages and/or absolute 
counts were available for 406 children at the start of ARV 
therapy.  The median CD4 percentage (interquartile range) was 
11.7% (7, 17.3), 266/402 (66.2%) had a CD4 percentage < 15% 
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and 41/402 (10.2%) had a CD4 percentage r 15%. According 
to the CDC classification 18/406 (4.4%) had no immune 
suppression (immune category 1), 77/406 (19%) moderate 
immune suppression (immune category 2) and 311/406 
(76.6%) severe immune suppression (immune category 3). At 
baseline the median viral load (interquartile range) was 380 000 
copies/ml (140 000, 1 292 000), and 111/367 (30.2%) had an 
initial viral load > 1 million copies/ml. The nutritional status 
of the children at the start of ARV therapy showed that 116/408 
(28.4%) were moderately underweight, 116/408 (28.4%) 
severely underweight, 129/406 (31.8%) moderately stunted, 
142/406 (35.2%) severely stunted, 55/390 (14.1%) moderately 
wasted and 26/390 (6.7%) severely wasted. The children were 
initiated on an ARV treatment regimen comprising two NRTIs 
plus either a PI (208/409 (50.9%)) or an NNRTI (201/409 
(49.1%)).
After 1 year on ARV therapy, 269/409 (65.8%) were alive and 
continued to be managed at RCH, 46/409 (11.2%) had been 
transferred to another ARV treatment site for continuation of 
HAART, 63/409 (15.4%) had died, 19/409 (4.6%) were lost 
to follow-up and treatment had been discontinued in 12/409 
(2.9%) because of sub-optimal adherence. The Kaplan-Meier 
survival estimate for all children (N = 407) at 1 year was 84% 
(95% confidence interval (CI) 80 - 87%). Survival for WHO 
clinical stage 2 (N = 3), stage 3 (N = 149) and stage 4 (N  = 
255) was 100%, 96% (95% CI 91 - 98%) and 77% (95% CI 71 
- 82%) respectively (Fig. 1). On univariate analysis, survival 
was adversely affected in children with WHO stage 4 v. stage 2 
and 3 disease (hazard ratio (HR): 6.19 (95% CI 2.67 - 14.36), p = 
0.000), age < 12 months (HR: 2.81 (95% CI 1.71 - 4.61), 
p = 0.000), those with a viral load r 1 million copies/ml 
(HR: 2.80 (95% CI 1.63 - 4.80, p = 0.000) and those on a PI 
regimen (HR: 3.84 (95% CI 2.12 - 6.96), p = 0.000). Survival 
was unaffected by gender, CDC immunological category, 
absolute CD4 count and CD4 percentage. On multivariate 
analysis of all children, after adjusting for WHO clinical stage 
and age, the absolute CD4 count did affect survival. In a 
separate multivariate model including only children on whom 
an initial viral load was done (N  = 367), more severe WHO 
clinical stage, lower absolute CD4 count, viral load r 1 million 
copies/ml and taking a PI-based regimen were independently 
associated with poorer survival; however, age was no longer a 
significant predictor of mortality (p = 0.119) (Table I).
One-year viral load results were available for 264/269 
children who continued their management at RCH throughout 
the first year on HAART.  The proportion of these children 
with a viral load less than 400 copies/ml was 184/264 (69.7%). 
A further 26/264 (9.8%) had a viral load between 400 and 5 000 
copies/ml. A more detailed analysis of the cohort after 1 year 
of HAART is presented in Table II. This analysis is confined to 
children with complete results at both baseline and 1 year, for 
each parameter evaluated.
Discussion
The treatment programme at RCH is an integral component 
of a complex network of primary, secondary and tertiary 
ARV treatment sites that was established by the HIV/AIDS 
Directorate of the Western Cape from March 2004 onwards to 
respond to the HIV epidemic among children in the province. 
Through donor funds several institutions, including RCH, 
began treating children before 2004 but all have since been 
incorporated into the provincial network.17 Central to the 
provincial response to the paediatric epidemic is a successful 
perinatal prevention programme. The perinatal programme has 
undergone significant improvement in the last few years and 
could in the foreseeable future reduce the absolute perinatal 
transmission rate to less than 5%. This should decrease the 
paediatric HIV burden and ultimately lead to improved care 
for children with established infection. The development of 
treatment sites for children has generally lagged behind adult 
care. However, this problem has largely been corrected and at 
Table I.  Predictors of death in children receiving HAART
Adjusted HR 95% CI p-value
Cox-proportional 
hazards model for 
all children (N = 407)  
  WHO stage 4 5.26 2.25 - 12.32 0.000
  Age < 12 months 2.46 1.48 - 4.09 0.001
  CD4 absolute count 
  (per 100 cell increase) 0.93 0.88 - 0.98 0.013
Cox-proportional 
hazards model for 
children on whom 
initial viral load was 
measured (N = 367)  
  WHO stage 4 3.84 1.45 - 10.20 0.007
  CD4 absolute count 
  (per 100 cell increase) 0.90 0.84 - 0.96 0.002
  Viral load r 1 million 1.84 1.03 - 3.29 0.041
  PI-based regimen 2.25 1.10 - 4.61 0.026
Adjusted HR = adjusted hazard ratio;  95% CI = 95% confidence interval; PI = 
protease inhibitor.
Fig. 1. Kaplan-Meier survival estimates by WHO clinical stage.
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the end of March 2006, 37/43 (86%) ARV treatment sites in the 
province were treating children.25
This retrospective study addressed the effectiveness of 
HAART in a setting characterised by high unemployment and 
low rates of secondary school completion among caregivers.26
As with many retrospective studies some of the data were 
not available for analysis. Furthermore, children were 
retrospectively restaged using the latest WHO clinical staging 
system and the CDC immunological staging system. While 
immunological classification is based on objective criteria, 
retrospective clinical staging is dependent on the quality and 
availability of the clinical records. The latest WHO staging 
guidelines include clinical case definitions for each staging 
criterion, which does improve the objectivity of staging.22
Furthermore, the impact of HAART on the frequency and 
severity of infectious complications and on hospitalisation 
rates was not evaluated.  Despite these limitations, we believe 
that the results of this study are an accurate reflection of the 
response to HAART at our institution.    
Baseline characteristics described the clinical condition of the 
children at the time of starting HAART. Striking features were 
the high frequency of advanced, WHO clinical stage 4 disease 
(62.7%), advanced immune suppression (76.6%) and pervasive 
nutritional deficiencies. The median age of 23 months, the high 
proportion of children below 2 years of age and the adverse 
survival associated with an age of  less than 1 year reflect the 
high burden of severe disease among young children treated 
at our institution. These findings are consistent with natural 
history studies of paediatric HIV infection in Africa that have 
reported mortality rates in excess of 50% by the age of 2 years.27
In contrast, previous publications on paediatric ARV treatment 
programmes from low- and middle-income countries have 
documented limited experience with treating children less 
than 2 years of age.13,15,16  Treating young infected children 
may be particularly challenging as they often have complex 
medical problems, the state of knowledge of the use of ARVs 
in the very young is incomplete and obtaining blood samples 
for monitoring may be technically challenging. For these 
reasons health professionals have generally been reluctant to 
treat young children with HIV infection.28 Special attention is 
needed to ensure that health institutions in resource-limited 
settings are adequately capacitated to address the medical 
needs of this vulnerable group.                        
Given the severity of the clinical and immunological status 
of the children at baseline and the high proportion of young 
children in the programme, the overall estimated survival 
after 1 year of 84% (95% CI 80 - 87%) was reasonable. The 
probability of survival on HAART after 1 year in a study 
conducted in Côte d’Ivoire was 91% (95% CI 82.1 - 95.6%). In 
that study 107 children were enrolled, hence the wider 95% 
confidence interval, the median age at enrolment was 7.2 years, 
which was higher than in our study, and severe clinical disease 
was present in only 12.8%, suggesting that children enrolled in 
that study were relatively less ill at the start of HAART.13 The 
marked, but expected, predictable pattern of decline in 1-year 
survival between children with WHO stage 2 and 3 disease 
(96% (95% CI 91 - 98%)) compared with those with WHO stage 
4 disease (77% (95% CI 71 - 82%)) and the adverse effect of viral 
load r 1 million on survival in our study suggests that the high 
proportion of children enrolled with severe disease adversely 
affected overall survival rates. While the Côte d’Ivoire study 
showed significantly lower survival in children with a CD4 
percentage < 5%, interestingly in our study survival was not 
associated with CD4 percent or CDC immunological category.13
However, on multivariate analysis higher absolute CD4 counts 
were independently associated with improved survival, with 
a 7% (95% CI 2 - 12%) reduction in mortality for every 100-
cell increase in CD4 count. In the present study, univariate 
Table II. Comparison of status at baseline and 1 year after commencing HAART 
Parameter Baseline 1 year p-value
Median WAZ; IQR -2.17; -3.09, -1.12 -0.93; -1.66, -0.13 0.000
  Moderate underweight 76/266 (28.6%) 42/266 (15.8%) 0.000
  Severe underweight 73/266 (27.4%) 9/266 (3.4%) 0.000
Median HAZ; IQR -2.51; -3.41, -1.72 -1.92; -2.67, -1.14 0.000
  Moderate stunting 89/264 (33.7%) 77/264 (29.2%) 0.3
  Severe stunting 89/264 (33.7%) 46/264 (17.4%) 0.000
Median WHZ; IQR -0.63; -1.77, 0.4 0.43; -0.37, 1.14 0.000
  Moderate wasting 34/254 (13.4%) 3/254 (1.2%) 0.000
  Severe wasting 18/254 (7.1%) 3/254 (1.2%) 0.000
Median CD4%; IQR 12.0; 7.2, 17.2 24.0; 18.74, 30.0 0.000
  CD4% < 15% 173/261 (66.3%) 28/261 (10.7%) 0.000
  CD4% r 25% 26/261 (10.0%) 118/261 (45.2%) 0.000
Median log10 VL; IQR 5.54; 5.15, 6.08 2.6; 2.6, 3.27 0.000
  VL > 106 copies/ml 69/241 (28.6%) 3/241 (1.2%) 0.000
  VL < 400 copies/ml 0/241 168/241 (69.7%) 0.000
IQR = interquartile range; WAZ = weight-for-age z-score; HAZ = height-for-age z-score; WHZ = weight-for-height z-score; VL = viral load.
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analysis and the multivariate model on all children suggest 
that children under 1 year of age experience adverse survival. 
However, the separate multivariate model in children in whom 
an initial viral load was measured showed that after adjusting 
for viral load, age does not affect survival. This suggests that 
poorer survival in very young children is due to their more 
severe disease rather than their age per se. While univariate 
analysis and the multivariate submodel including viral load 
showed greater mortality in children receiving a PI-based 
regimen, this was not confirmed in the main multivariate 
model for all children in the study. The apparent adverse 
effect of a PI-based regimen may therefore largely be due to 
preferential administration of PIs to younger children who 
tended to have more severe disease. Alternatively, regimen 
and age were co-linear variables, which may explain why age 
was excluded and replaced with regimen in the multivariate 
submodel analysis.
Table II summarises the effect of 1 year of HAART on 
growth, immune reconstitution and viral replication in children 
for whom complete data existed. Notably, of 264 children 
who remained on HAART at RCH 69.7% had a viral load 
below 400 copies/ml. This result is consistent with published 
efficacy studies where the percentage of children with viral 
loads < 400 copies/ml varied between 63% and 87%.29 The 
future management of the 30.3% of children with detectable 
viral loads is of concern. Current national treatment guidelines 
have made provision for two rounds of ARV therapy. Beyond 
second-line therapy there is no specific recommendation for the 
provision of salvage regimens.21 This particular issue has to be 
confronted in South Africa and other middle-income countries 
where resources exist to manage patients beyond second-line 
therapy and where a sizeable proportion of children are likely 
to fail second-line therapy in the near future.           
After 1 year on HAART, 11.3% of the children had been 
transferred to another ARV treatment site for ongoing care. 
Most were referred to their local community clinics in the 
greater Cape Town region. This development represents 
another important component of the provincial paediatric 
programme, namely the provision of treatment for infected 
children at the most appropriate level within the health care 
system. Referral of clinically stable children on HAART 
to community institutions accompanied by the transfer of 
appropriate paediatric clinical skills is a necessary strategy 
in countries with high HIV prevalence rates. This approach 
will alleviate the congestion experienced at referral hospitals, 
allowing them to address the more technically challenging 
aspects of the disease, including children with complex 
pathology, serious infectious complications, adverse events 
including immune reconstitution inflammatory syndrome, 
and many of the younger children. The success of this 
initiative, which has gained momentum over the last year, is 
best illustrated with the official provincial statistics. At the 
end of March 2004, 78.4% (537/685) of all children treated 
with HAART in the province were managed at the three 
paediatric referral hospitals in Cape Town namely RCH, 
Groote Schuur Hospital and Tygerberg Hospital.30 At the end 
of March 2006, this figure had declined to 49.5% (995/2009) of 
the total number of children on treatment.25 Furthermore, the 
referral hospitals in Cape Town have been actively involved 
in developing the clinical capacities of health professionals at 
community institutions and providing telephonic and on-site 
consultation support to these institutions.
In conclusion, while this study has demonstrated that 
HAART is able to improve the health of many HIV-infected 
children with advanced disease, including those less than 
2 years of age in a middle-income country, it has generated 
concern about treatment beyond second-line therapy.  
Ms Pheliwe Ranuga is acknowledged for clerical assistance, and 
staff members of the Infectious Diseases Clinic and Immunology 
Laboratory at RCH for service excellence. Donations to fund the 
initial part of the treatment programme were received from Syfrets 
Trust Ltd, Merck (Pty) Ltd, Bristol-Myers Squibb Foundation, 
Durbanville High School and the University of Cape Town.
References
  1.   WHO and UNAIDS. Treating 3 million by 2005. Making it happen: The WHO strategy, 2003. 
http://www.who.int (accessed 3 November 2005).
  2.   Boerma JT, Stanecki KA, Newell ML, et al. Monitoring the scale-up of antiretroviral therapy 
programmes: methods to estimate coverage. Bull World Health Organ 2006; 84: 145-150.
  3.   UNICEF. UNICEF and UNAIDS launch global campaign to invigorate action for the millions 
of children affected by HIV/AIDS. http://www.unicef.org (accessed 3 November 2005).
  4.   de Martino M, Tovo P, Balducci M,  et al. Reduction in mortality with availability of 
antiretroviral therapy for children with perinatal HIV-1infection. JAMA 2000; 284: 190-197.   
  5.   Brogley S, Williams P, Seage GR,  et al. Antiretroviral treatment in pediatric HIV infection in 
the United States. From clinical trials to clinical practice. JAMA 2005; 293: 2213-2220.
  6.   Miller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and 
body composition in human immunodeficiency virus type-1-infected children. Pediatrics 2001; 
107(5): e77. http://www.pediatrics.org/cgi/contents/full/107/5/e77 (accessed 19 May 2006).
  7.   Granados JMS, Amador JTR, De Miguel SF,  et al. Impact of highly active antiretroviral 
therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected 
children. Pediatr Infect Dis J 2003; 22: 863-867.
  8.   Gibb DM, Duong T, Tookey PA,  et al. Decline in mortality, AIDS and hospital admissions 
in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327:
1019-1024.
  9.   Viani RM, Araneta MRG, Deville JG, Spector SA. Decrease in hospitalisation and mortality 
rates among children with perinatally acquired HIV type 1 infection receiving highly active 
antiretroviral therapy. Clin Infect Dis 2004; 39: 725-731.
10.   Yogev R. Balancing the upside and downside of antiretroviral therapy in children. JAMA
2005; 293: 2272-2274.
11.    McConnell MS, Byers RH, Frederick T,  et al. Trends in antiretroviral therapy use and 
survival rates for a large cohort of HIV-infected children and adolescents in the United States, 
1989-2001. J Acquir Immune Defic Syndr 2005; 38: 488-494.
12.   Lee GM, Gortmaker SL, McIntosh K, Hughes MD, Oleske JM and Pediatric AIDS Clinical 
Trials Group Protocol 219C Team. Quality of life for children and adolescents: Impact of HIV 
infection and antiretroviral therapy. Pediatrics 2006; 117: 273-283.
13.   Fassinou P, Elenga N, Rouet F,  et al. Highly active antiretroviral therapies among HIV-1-
infected children in Abidjan, Côte d’Ivoire. AIDS 2004; 18: 1905-1913.
14.   Matida LH, Marcopito LF, Succi RCD,  et al. Improving survival among Brazilian children 
with perinatally-acquired AIDS. Braz J Infect Dis 2004; 8: 419-423.
15.   Puthanakit T, Oberdorfer A, Akarathum N,  et al. Efficacy of highly active antiretroviral 
therapy in HIV-infected children participating in Thailand’s national access to antiretroviral 
program. Clin Infect Dis 2005; 41: 100-107.
16.   Lodha R, Upadhyay A, Kabra SK. Antiretroviral therapy in HIV-1 infected children. Indian
Pediatr 2005; 42: 789-796.
17.   Eley B, Nuttall J, Davies M,  et al. Initial experiences of a public sector antiretroviral treatment 
programme for HIV-infected children and their infected parents. S Afr Med J 2004; 94: 643-
646.
18.   Paediatric European Network for the Treatment of AIDS (PENTA) steering committee. 
PENTA Guidelines for the Use of Antiretroviral Therapy in Paediatric HIV Infection, 2002. 
http://www.ctu.ac.uk/PENTA/ (accessed 19 July 2002).
19.   World Health Organization. Scaling up antiretroviral therapy in resource-limited settings, 
2004 revision. http://www.who.int (accessed 20 January 2005). 
20.   The Working Group on Antiretroviral Therapy and Medical Management of HIV-infected 
Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, 2006. 
ORIGINAL ARTICLES
993
September 2006, Vol. 96, No. 9  SAMJ
http://www.aidsinfo.nih.gov (accessed 1 April 2006).
21.   Department of Health of South Africa. Guidelines for the management of HIV-infected 
children, 2005. http://www.doh.gov.za/docs/hiv-f.html (accessed 25 October 2005).
22.   World Health Organization. Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS 
Case Definitions for Surveillance, African Region, 2005. http://www.who.int (accessed 1 April 
2006).
23.   Centers for Diseases Control and Prevention. 1994 revised classification system for human 
immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43: No. 
RR-12.
24.   World Health Organization. Global database on child growth and malnutrition. http://www.
who.int/nutgrowthdb/about/introduction/en/index.html (accessed 15 April 2006).
25.   HIV/AIDS Directorate, Western Cape Department of Health. Western Cape Antiretroviral 
Treatment Programme Monthly Report, Provincial Government of the Western Cape, March 
2006.
26.   Eley B, Nuttall J, Davies M,  et al. Initial experience of a public sector antiretroviral treatment 
programme for HIV-infected children in Cape Town, South Africa. In: 15th International AIDS 
Conference, 11 - 16 July 2004, Bangkok, Thailand, Abstract TuPeB4412.
27.   Newell M-L, Coovadia H, Cortina-Borja M,  et al. Mortality of infected and uninfected infants 
born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364: 1236-1243.
28.   Michaels D, Eley B, Ndhlovu L, Rutenberg N. Exploring current practices in paediatric ARV 
rollout and integration with early childhood programmes in South Africa: A rapid situational 
analysis, June 2006. http://www.popcouncil.org/pdfs/horizons/sapedssa.pdf (accessed 21 
July 2006).
29.   van Rossum AMC, Fraaij PLA, de Groot R. Efficacy of highly active antiretroviral therapy in 
HIV-1 infected children. Lancet Infect Dis 2002; 2: 93-102.
30.   HIV/AIDS Directorate, Western Cape Department of Health. Western Cape Antiretroviral 
Treatment Programme Monthly Report, Provincial Government of the Western Cape, March 
2004.
Accepted 9 August 2006.
Over the last 20 years studies focusing on malnutrition 
have helped to define the benefits of nutrition intervention. 
Malnutrition remains a widespread and largely unrecognised 
problem.1-2   
Malnutrition may be defined as a nutrition disorder resulting 
from reduced nutrient intake or impaired metabolism.  There is 
currently no ‘gold standard’ or single measure of malnutrition.3
Malnutrition impacts on the length of hospital stay (LOS), 
cost of stay, morbidity, mortality, infectious complications and 
quality of life, and deprives the patient of participating in usual 
family or social dynamics.4
Malnutrition is associated with children who are going 
through periods of rapid growth. Surveys of hospitalised 
patients in developed and developing countries have found a 
prevalence of 35 - 60% of patients nutritionally at risk with a 
further 25% of patients documented as having overnutrition.1,2,5
It has been argued by some that increased hospital stay 
may not be a result of malnutrition but rather underlying 
pathology.6  Despite improvements in nutritional therapy, in 
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Aim.  To determine the prevalence of malnutrition in 
hospitalised paediatric patients at Red Cross War Memorial 
Children’s Hospital.
Method.  A 1-day cross-sectional survey was completed in all 
medical and surgical wards and some specialist outpatient 
clinics.
Results.  A total of 227 children participated in the study. 
Thirty-five per cent of patients were moderately malnourished 
(b -2 z-score), of whom 70% had no road to health card with 
them.  Thirty-four per cent of children under 60 months of 
age received supplements in addition to a normal ward diet, 
7.8% were enterally fed and less than 1% were parenterally 
fed. Almost 14% of children were found to be overweight/
obese, which is higher than the national average of 6%.  The 
prevalence of HIV infection on the day of the audit was 
18% across all age groups compared with the Western Cape 
antenatal prevalence of 15.7% (2005).
Conclusion. The overall prevalence of undernutrition was 
34%, which is comparable with similar studies. However, the 
proportion of overweight children (14%) was greater than the 
national average.  In view of the level of malnutrition seen, 
a nutrition risk-screening tool, identifying risk factors for 
malnutrition such as food access and vulnerability, should be 
developed. The tool should be used to assess nutrition status 
and risk during the course of hospitalisation, in addition to 
planning appropriate nutrition care plan interventions for 
discharge.   
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some hospitalised paediatric groups many of the strategies 
remain ineffective in dealing with malnutrition and/or 
identifying it timeously.7
Growth failure and malnutrition are commonly seen in 
children with HIV, and are recognised as poor prognostic 
factors for short-term survival in addition to being sensitive 
markers for disease progression.8
Aim
The aim of this study was to determine the prevalence of 
malnutrition of children at Red Cross War Memorial Children’s 
Hospital via a 1-day cross-sectional survey.
Methods
The 1-day cross-sectional survey was undertaken in September 
2005 at Red Cross War Memorial Children’s Hospital. It 
included patients in all medical and surgical wards and 
in some specialist outpatient clinics. Ethical approval was 
obtained from the Ethics Committee, University of Cape Town.  
Dietitians were responsible for collecting anthropometric, 
biochemical, clinical and dietary information using a 
standardised proforma. 
Results
Two hundred and twenty-seven children were surveyed, of 
whom 52% were male, and 44% (N = 90) were less than 1 year 
of age. The LOS varied from < 24 hours to 295 days, with the 
overall average being 19.4 days (standard deviation (SD) 36.7).  
Table I indicates a comparison between the prevalence of 
malnutrition in a survey completed in 1999 versus the current 
2005 survey. Although the trends in respect of moderate to 
severe malnutrition with regard to height-for-age z-scores 
(HAZ) and weight-for-height z-scores (WHZ) are similar 
(28% v. 34% (HAZ) and 19% (WHZ)), there is a trend towards 
increasing prevalence of malnutrition.   
Eighty per cent (80%) of malnourished children (b -2 z-
scores) had an albumin level of < 35 g/l. No correlation could 
be found between haemoglobin (Hb) and malnutrition. On 
average those with an Hb of > 10 g/l had a WHZ of -1.6 z-
scores.  
Thirty-four per cent of children between the ages of 13 and 
60 months received nutrition supplementation, 7.8% were 
enterally fed and < 1% were parenterally fed. According to the 
national surveillance figures from the Department of Health 
7% of all infants are exclusively breastfed; the incidence of 
exclusive breastfeeding on the day of the audit was 12%. 
Of particular interest is the double disease burden (Table I) 
evident among the population surveyed. While the national 
average for overweight/obesity r +2 z-scores is 7.6%, the 
average of r +2 z found among the participants at Red Cross 
War Memorial Children’s Hospital was as high as 13.5%. The 
concern regarding this trend is the early rebound adiposity 
seen in the 13 - 60-month age group. 
Discussion   
In order to promote good nutrition status it is essential to 
develop and implement nutrition guidelines and support 
algorithms to assist with early appropriate interventions, 
which should ideally be planned by a dietitian.6 A nutrition 
risk-screening tool may determine the extent of malnutrition 
within a population and is associated with a decrease in LOS, 
morbidity and mortality and improved nutrition status.3,9
The results from this survey mirror findings by other centres 
with regard to malnutrition and LOS. However, limitations 
of the study should be noted, e.g. that it was only a 1-day 
sample, conducted during springtime. The overall prevalence 
of malnutrition in the population surveyed at Red Cross War 
Table I. Over- and undernutrition 
Prevalence of
moderate malnutrition          1999 survey
> -2 z-scores  < 12 months  13 - 60 months  > 60 months  Waterlow criteria
WAZ   40% (N = 39)  27% (N = 17)  29% (N = 22)  
HAZ   33.5% (N = 35)  31% (N = 20)  31% (N = 19)  28%
WHZ   27% (N = 27)  21% (N = 13)  14% (N = 19)  19%
WHZ   > 7 days
r- 2 Z scores   p = 0.0093
& LOS   (95% CI = 1.17 - 3.4)  
Overall   34%   32%   19%
Prevalence of 
overweight/obesity
r +2 z-scores  < 12 months  13 - 60 months  All ages
WAZ   13.5% (N = 13)  11% (N = 7)  6.6% (N = 20)
WHZ   9% (N = 7)  9.5% (N = 6)  7% (N = 16)
WAZ = weight-for-age z-score; HAZ = height-for- age z-score; WHZ = weight-for-height z-score; LOS = length of hospital stay.
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Memorial Children’s Hospital was 34% (including weight 
for age). Twenty per cent (20%) were wasted (weight for 
height) and 34% were stunted (height for age), compared 
with the national average of 10% wasting and 22% stunting 
respectively.10
Despite an active dietetic department in addition to 
each ward having a dedicated dietitian, the prevalence of 
malnutrition is still unacceptably high, with no discernable 
improvement over the last 7 years.  Confounding factors such 
as HIV/AIDS obviously play a role in the increasing disease 
burden. But can all findings be related to an increase in disease 
prevalence or are our strategies at treating malnutrition 
becoming less effective, especially as many of the HIV-infected 
children are receiving antiretrovirals? 
The HIV prevalence rate on the day of the study was 18% 
among all age groups, compared with the Western Cape 
antenatal prevalence of 15.7% (2005).11 While this figure may 
contribute to the prevalence of malnutrition seen among our 
population group, it does not entirely explain the continued 
high incidence recorded. This would suggest that other factors 
are contributing to the high prevalence of malnutrition, such as 
issues surrounding food security and vulnerability.
The Integrated Nutrition Programme has a targeted 
Nutrition Supplementation Programme (NSP) indicated for 
growth-faltering children. The programme is successful in 
providing nutrition products targeted at the individual for 
a period of 6 months. The NSP is currently unable to tackle 
issues around food security and vulnerability, so while disease-
related malnutrition may be successfully treated in a few, 
malnutrition as a result of socio-economic causes is unlikely 
to result in successfully rehabilitated patients unless socio-
economic issues are addressed.  
The results from this survey also indicate the evidence of a 
double disease burden among the population surveyed. The 
national average for overweight/obesity r +2 z-scores is 7.6%. 
The average found among the survey participants was as high 
as 13.5%. Most of this was seen in children under the age of 
5 years indicating that they had experienced early rebound 
adiposity.  Early rebound adiposity is associated with an 
increased risk of chronic diseases of lifestyle later in life. While 
it is outside of the scope of this audit to link those patients to 
disease profiles, it raises the question regarding the practice 
of aggressive ‘catch-up growth’ past the age of 2 years and 
whether or not we should be recommending concurrent linear 
growth in addition to weight gain alone.12
To date effective ways of treating malnutrition in this patient 
population group have remained elusive. Perhaps it is time 
to question strategies around malnutrition and nutrition 
supplementation in relation to food security and vulnerability 
to accommodate a sustainable access to food in vulnerable 
households.
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